HOME - Companies - Products
 
 
19 February 2025

TriAgenics Adds 20th International Patent to its Medical Device Portfolio


TriAgenics, the pioneer of fully guided tooth bud ablation, has announced the grant of four additional European patents, further establishing the company’s global IP position for a novel technology designed to prevent third molar formation. Germany, France, Italy, and the United Kingdom are the latest European countries to grant a patent for TriAgenics’ ablation probe system.

TriAgenics’ patented micro-ablation technology is the cornerstone behind Zero3 TBA, a preventive-care treatment for children ages 6–12. The treatment prevents the formation of third molars through the application of low-level, CT-guided microwave energy. This new dental modality is based on microwave ablation techniques commonly used in the medical field. TriAgenics plans to introduce Zero3 TBA to the U.S. dental market in 2025, following clearance from the U.S. Food and Drug Administration.

Following FDA clearance, dentists will send patient CBCT and intraoral scans to TriAgenics, which will fabricate custom Zero3 kits and ship them to dentists to perform the one-minute treatment using TriAgenics’ proprietary ablation technology.

TriAgenics believes the economic impact of Zero3 TBA treatment will be massive. Total expenditures associated with extracting third molars and correcting related problems are estimated to be nearly $5 billion in the U.S. alone.

TriAgenics estimates its total addressable market will be greater than $2.5 billion annually when Zero3 TBA treatment becomes the new standard of care in the U.S.

About TriAgenics

TriAgenics is a disruptive oral healthcare company that has pioneered the development of a one-minute treatment designed to prevent third molars from ever forming. Based on extensive animal trials, TriAgenics’ Zero3 TBA system is expected to eliminate all pain and complications normally associated with third molar extraction. TriAgenics’ mission is to provide dentists and their patients with a non-surgical alternative that has no painful recovery or need to miss work or school.


Source: www.triagenics.com

Related articles

TriAgenics, Inc., a privately held company pioneering a non-surgical approach to third molar (wisdom tooth) prevention, today announced that it expanded its Series B-1 funding round in response to...


News     05 May 2025

TriAgenics Appoints New CEO

TriAgenics, Inc., pioneer of Zero3 TBA, a fully guided tooth bud ablation system designed to prevent third molar formation, announced that David Thrower has been named president and CEO.


Specialty1 Partners (S1P), the nation’s leading doctor-founded and doctor-led specialty dental partnership organization, recently announced its newest joint venture partnership wit


Rob Brian brings more than 15 years of dental industry experience to Menlo Dental Transitions, where he will advise dentists throughout Utah and the surrounding region.


Black Talon Security has announced a strategic reseller agreement with Henry Schein One’s TechCentral to bring its EAGLEi cybersecurity platform to dental practices across the Unit


Read more

Esthetic Implants - Edra Publishing book cover

Esthetic Implants is an Edra professional dentistry reference focused on clinical practice, education and treatment planning.


Partnership with Eversmile makes o scillating s ystem available through HSO in the United States.


National trauma data show Medicaid coverage rose from 16% to 24% after ACA implementation, while self-pay cases declined, suggesting broader insurance access for patients needing u


The Investment Grade Practice Assessment reveals opportunities to strengthen revenue, systems, leadership, and long-term business health


Rick Mediavilla, DDS, FAGD, associate professor and associate dean of admission, student and alumni affairs, had the honor of announcing each of the 79 graduates, their plans follo


 
 
 
 

 
 
 
 

Most popular

 
 

Events